There have been significant advances in cancer treatment over the past several years
through the use of chemotherapy, radiation therapy, molecularly targeted therapy, and
immunotherapy. Despite these advances, treatments such as monotherapy or monomodality
have significant limitations. There is increasing interest in using these strategies in
combination; however, it is not completely clear how best to incorporate molecularly targeted
and immune-targeted therapies into combination regimens. This is particularly pertinent …